Health CareMedical Equipment and Services
  • Price (SEK)162.90
  • Today's Change-3.90 / -2.34%
  • Shares traded269.37k
  • 1 Year change-31.38%
  • Beta1.2521
Data delayed at least 15 minutes, as of Jun 23 2022 17:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

AddLife AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The Company operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The Company operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.

  • Revenue in SEK (TTM)8.84bn
  • Net income in SEK717.60m
  • Incorporated2014
  • Employees2.12k
  • Location
    AddLife ABBrunkebergstorg 5, Box 3145STOCKHOLM 103 62SwedenSWE
  • Phone+46 842003830
  • Websitehttps://www.add.life/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ALIF B:STO since
O'Flynn Medical LtdDeal completed01 Apr 202201 Apr 2022Deal completed-38.11%--
BioCat GmbHDeal completed01 Apr 202201 Apr 2022Deal completed-38.11%--
MBA Incorporado SLDeal completed22 Dec 202122 Dec 2021Deal completed-52.28%125.24m
Telia Sverige AB-Telia Health MonitoringDeal completed20 Dec 202120 Dec 2021Deal completed-49.19%--
Camanio ABAnnounced01 Dec 202101 Dec 2021Announced-53.05%7.21m
Data delayed at least 15 minutes, as of Jun 23 2022 17:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Bonesupport Holding AB234.40m-81.69m4.41bn86.00--17.72--18.80-1.27-1.273.653.860.60410.49137.012,547,804.00-21.05-35.30-24.97-44.5789.6087.87-34.85-84.283.84-73.970.0796--17.7115.2715.66--19.98--
Calliditas Therapeutics AB279.08m-581.89m5.08bn71.00--5.92--18.19-11.38-11.385.4716.380.20771.0888.214,228,500.00-43.88-31.46-49.82-34.6817.60---211.31-288.515.36-88.310.1976--26,141.08---15.41--145.12--
Zealand Pharma A/S373.48m-1.38bn6.58bn345.00--5.99--17.61-22.16-23.126.0216.420.12971.993.89731,901.40-47.76-31.81-57.58-37.0762.29---368.33-247.194.78--0.5268---17.194.85-20.24--53.47--
Surgical Science Sweden AB488.71m101.20m7.69bn224.0059.522.0954.2715.742.542.5411.7372.320.19352.226.802,338,335.004.013.414.273.6769.0778.8020.7115.422.18--0.04320.00249.9847.90452.6692.434.25--
Nykode Therapeutics ASA346.26m-99.18m9.12bn128.00--4.78--26.33-0.3843-0.38431.186.400.1433--3.823,301,744.00-4.1025.30-4.5327.55-----28.6446.19----0.0357---84.20311.05-106.29--157.24--
BioGaia AB866.99m222.13m9.66bn189.0045.164.9839.4411.,191,557.0010.6418.7011.3821.2773.8174.1825.6226.20----0.0075.305.097.999.204.2238.51-0.6484
Camurus AB694.95m-69.32m10.57bn149.00--12.35--15.21-1.27-1.2712.7315.560.65510.86015.814,695,635.00-6.53-27.66-8.06-33.8286.2186.73-9.98-84.902.64-66.370.0273--78.7439.4945.93--1.59--
Swedencare AB (publ)1.02bn39.41m13.74bn517.00250.762.1285.4813.480.34660.34668.3441.010.19242.107.473,640,225.000.74384.780.78735.0748.7057.823.8711.941.113.350.197432.49221.7770.4663.7641.06----
Karo Pharma AB2.96bn-17.25m13.88bn242.00--1.9858.914.69-0.0617-0.061713.1325.680.2359----12,262,750.00-0.13531.79-0.17612.4957.6255.56-0.57377.451.691.060.49643.502.7253.52-121.27---4.89--
AddLife AB8.84bn717.60m19.20bn2.12k27.754.3614.812.175.875.8772.2637.351.055.117.114,903,219.008.539.0316.5417.1036.6135.748.147.570.31399.790.535734.1751.57--38.78------
Bavarian Nordic A/S2.73bn-668.08m24.53bn759.00--2.31--8.99-7.48-7.4830.41104.700.18212.657.092,500,494.00-4.46-2.42-5.17-2.9330.0545.79-24.49-11.372.24-7.690.3584--2.4613.52-267.47--49.64--
Vitrolife AB2.05bn304.76m29.12bn1.17k84.381.8759.4314.182.552.5516.93114.690.18643.036.304,809,944.002.788.882.949.5559.3163.5314.9324.081.1723.180.136523.2234.9414.4518.8712.3635.349.00
ALK-Abello A/S5.82bn366.55m35.96bn2.57k106.267.4448.866.181.161.1618.4516.600.68921.345.891,596,374.004.34-0.51155.47-0.616361.8558.116.30-0.81180.975620.060.146--12.175.44776.00-4.103.17--
Data as of Jun 23 2022. Currency figures normalised to AddLife AB's reporting currency: Swedish Krona SEK

Institutional shareholders

43.83%Per cent of shares held by top holders
HolderShares% Held
SEB Investment Management ABas of 28 Feb 202210.99m9.33%
Swedbank Robur Fonder ABas of 19 Apr 20228.18m6.94%
Fidelity Management & Research Co. LLCas of 30 Apr 20226.70m5.69%
Capital Research & Management Co. (World Investors)as of 25 Oct 20215.32m4.52%
Handelsbanken Fonder ABas of 31 May 20225.21m4.42%
ODIN Forvaltning AS (Sweden)as of 31 May 20223.50m2.97%
ODIN Forvaltning ASas of 31 May 20223.33m2.83%
AMF Fonder ABas of 01 Mar 20222.96m2.51%
The Vanguard Group, Inc.as of 02 Jun 20222.92m2.48%
Lannebo Fonder ABas of 28 Feb 20222.54m2.16%
More ▼
Data from 31 Mar 2022 - 31 May 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.